p53 and disease progression in patients with non-small cell lung cancer

E. R. Sauter, J. L. Gwin, J. Mandel, S. M. Keller

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (P = 0.06), and p53 expression correlated significantly (P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalSurgical Oncology
Volume4
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Disease Progression
Survival
Squamous Cell Carcinoma
Histology
Neoplasms
Lymph Node Excision
Disease-Free Survival
Monoclonal Antibodies
Lung
Incidence
Population

Keywords

  • Lung cancer
  • Mediastinal lymph node dissection
  • p53
  • Prognosis
  • Protein expression

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Sauter, E. R., Gwin, J. L., Mandel, J., & Keller, S. M. (1995). p53 and disease progression in patients with non-small cell lung cancer. Surgical Oncology, 4(3), 157-161.

p53 and disease progression in patients with non-small cell lung cancer. / Sauter, E. R.; Gwin, J. L.; Mandel, J.; Keller, S. M.

In: Surgical Oncology, Vol. 4, No. 3, 1995, p. 157-161.

Research output: Contribution to journalArticle

Sauter, ER, Gwin, JL, Mandel, J & Keller, SM 1995, 'p53 and disease progression in patients with non-small cell lung cancer', Surgical Oncology, vol. 4, no. 3, pp. 157-161.
Sauter ER, Gwin JL, Mandel J, Keller SM. p53 and disease progression in patients with non-small cell lung cancer. Surgical Oncology. 1995;4(3):157-161.
Sauter, E. R. ; Gwin, J. L. ; Mandel, J. ; Keller, S. M. / p53 and disease progression in patients with non-small cell lung cancer. In: Surgical Oncology. 1995 ; Vol. 4, No. 3. pp. 157-161.
@article{5ffb8a0f456a4aa39c6635843eded6b4,
title = "p53 and disease progression in patients with non-small cell lung cancer",
abstract = "Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53{\%} of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (P = 0.06), and p53 expression correlated significantly (P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.",
keywords = "Lung cancer, Mediastinal lymph node dissection, p53, Prognosis, Protein expression",
author = "Sauter, {E. R.} and Gwin, {J. L.} and J. Mandel and Keller, {S. M.}",
year = "1995",
language = "English (US)",
volume = "4",
pages = "157--161",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - p53 and disease progression in patients with non-small cell lung cancer

AU - Sauter, E. R.

AU - Gwin, J. L.

AU - Mandel, J.

AU - Keller, S. M.

PY - 1995

Y1 - 1995

N2 - Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (P = 0.06), and p53 expression correlated significantly (P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.

AB - Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (P = 0.06), and p53 expression correlated significantly (P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.

KW - Lung cancer

KW - Mediastinal lymph node dissection

KW - p53

KW - Prognosis

KW - Protein expression

UR - http://www.scopus.com/inward/record.url?scp=0029090463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029090463&partnerID=8YFLogxK

M3 - Article

C2 - 7582188

AN - SCOPUS:0029090463

VL - 4

SP - 157

EP - 161

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -